Innovent Biologics Shares Rise Over 3% on Exclusive Licensing Deal for IBI355 and Upcoming SjD Phase II Study

Stock News07-15 09:40

Shares of Innovent Biologics (ASX: 01801) have climbed more than 3%. At the time of writing, the stock is up 3.28% to HK$93, with a trading turnover of HK$101 million.

Recent Developments

On July 14th, the company announced it has entered into an exclusive licensing agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO) for IBI355, a third-generation Fc-silent anti-CD40L antibody, which was previously under Spero's development code SP001.

Under the terms of the agreement, Innovent Biologics has granted Spero exclusive rights to develop, research, manufacture, and commercialize IBI355 globally, excluding the Greater China region. Innovent Biologics retains all rights to the product within Greater China.

Clinical Trial Plans

Spero intends to initiate a Phase II clinical study for IBI355 in patients with IgG4-RD in the second quarter of 2027. Innovent Biologics plans to commence a Phase II clinical study for IBI355 in the treatment of SjD in China by early 2027.

Financial Terms

As part of the agreement, Innovent Biologics will receive an upfront payment, along with development, registration, and sales milestone payments, in a deal valued at approximately $1.1 billion. The company will also be entitled to receive tiered royalties on future net sales of the product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133399981?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133399981","market":"fut","top_or_hot":-1,"title":"Innovent Biologics Shares Rise Over 3% on Exclusive Licensing Deal for IBI355 and Upcoming SjD Phase II Study","media":"Stock News","content":"<p>Shares of <b>Innovent Biologics</b> (<b>ASX: 01801</b>) have climbed more than 3%. At the time of writing, the stock is up 3.28% to HK$93, with a trading turnover of HK$101 million.<br><br>\n<b>Recent Developments</b><br><br>\nOn July 14th, the company announced it has entered into an exclusive licensing agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO) for IBI355, a third-generation Fc-silent anti-CD40L antibody, which was previously under Spero's development code SP001.<br><br>\nUnder the terms of the agreement, Innovent Biologics has granted Spero exclusive rights to develop, research, manufacture, and commercialize IBI355 globally, excluding the Greater China region. Innovent Biologics retains all rights to the product within Greater China.<br><br>\n<b>Clinical Trial Plans</b><br><br>\nSpero intends to initiate a Phase II clinical study for IBI355 in patients with IgG4-RD in the second quarter of 2027. Innovent Biologics plans to commence a Phase II clinical study for IBI355 in the treatment of SjD in China by early 2027.<br><br>\n<b>Financial Terms</b><br><br>\nAs part of the agreement, Innovent Biologics will receive an upfront payment, along with development, registration, and sales milestone payments, in a deal valued at approximately $1.1 billion. The company will also be entitled to receive tiered royalties on future net sales of the product.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Shares Rise Over 3% on Exclusive Licensing Deal for IBI355 and Upcoming SjD Phase II Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Shares Rise Over 3% on Exclusive Licensing Deal for IBI355 and Upcoming SjD Phase II Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-15 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>Innovent Biologics</b> (<b>ASX: 01801</b>) have climbed more than 3%. At the time of writing, the stock is up 3.28% to HK$93, with a trading turnover of HK$101 million.<br><br>\n<b>Recent Developments</b><br><br>\nOn July 14th, the company announced it has entered into an exclusive licensing agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO) for IBI355, a third-generation Fc-silent anti-CD40L antibody, which was previously under Spero's development code SP001.<br><br>\nUnder the terms of the agreement, Innovent Biologics has granted Spero exclusive rights to develop, research, manufacture, and commercialize IBI355 globally, excluding the Greater China region. Innovent Biologics retains all rights to the product within Greater China.<br><br>\n<b>Clinical Trial Plans</b><br><br>\nSpero intends to initiate a Phase II clinical study for IBI355 in patients with IgG4-RD in the second quarter of 2027. Innovent Biologics plans to commence a Phase II clinical study for IBI355 in the treatment of SjD in China by early 2027.<br><br>\n<b>Financial Terms</b><br><br>\nAs part of the agreement, Innovent Biologics will receive an upfront payment, along with development, registration, and sales milestone payments, in a deal valued at approximately $1.1 billion. The company will also be entitled to receive tiered royalties on future net sales of the product.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1133399981","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133399981","pubTimestamp":1784079655,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of Innovent Biologics (ASX: 01801) have climbed more than 3%. At the time of writing, the stock is up 3.28% to HK$93, with a trading turnover of HK$101 million. Recent Developments On July...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","KCAI":"KraneShares China Alpha Index ETF","BK1589":"北水核心资产","BK4588":"碎股","01801":"信达生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK4585":"ETF&股票定投概念","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD"},"translate_title":"IBI355 独家许可协议和即将进行的 SjD II 期研究，信达生物股价上涨超过 3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURE":1,"VXUS":1,"01801":1,"KCAI":1},"content_text":"Shares of Innovent Biologics (ASX: 01801) have climbed more than 3%. At the time of writing, the stock is up 3.28% to HK$93, with a trading turnover of HK$101 million.\nRecent Developments\nOn July 14th, the company announced it has entered into an exclusive licensing agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO) for IBI355, a third-generation Fc-silent anti-CD40L antibody, which was previously under Spero's development code SP001.\nUnder the terms of the agreement, Innovent Biologics has granted Spero exclusive rights to develop, research, manufacture, and commercialize IBI355 globally, excluding the Greater China region. Innovent Biologics retains all rights to the product within Greater China.\nClinical Trial Plans\nSpero intends to initiate a Phase II clinical study for IBI355 in patients with IgG4-RD in the second quarter of 2027. Innovent Biologics plans to commence a Phase II clinical study for IBI355 in the treatment of SjD in China by early 2027.\nFinancial Terms\nAs part of the agreement, Innovent Biologics will receive an upfront payment, along with development, registration, and sales milestone payments, in a deal valued at approximately $1.1 billion. The company will also be entitled to receive tiered royalties on future net sales of the product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133399981","isCrawlerRequest":true}